CCR3 inhibition for ocular angiogenesis and macular degeneration
US11345756B2 · kind B2 · utility
0Cited by
3References
12Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 29, 2019 |
| Grant date | May 31, 2022 |
| Priority date | — |
| Expiry date | Oct 15, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.